Home ยป Publications

Publications

  1. Salas-Escabillas DJ, Hoffman MT, Brender SM, Moore JS, Wen HJ, Benitz S, Davis ET, Long D, Wombwell AM, Chianis ERD, Allen-Petersen BL , Steele NG, Sears RC, Matsumoto I, DelGiorno KE, Crawford HC. Tuft cells transdifferentiate to neural-like progenitor cells in the progression of pancreatic cancer. Dev Cell. 2024 Dec 19;. doi: 10.1016/j.devcel.2024.12.003. PMID: 39721583
  2. Tinsley SL, Chianis ERD, Shelley RA, Mall GK, Dhiman A, Baral G, Kothandaraman H, Thoma MC, English IA, Daniel CJ, Acosta LCS, Solorio L, Atallah Lanman N, Pasca di Magliano M, Narla G, Dykhuizen EC, Sears RC, Allen-Petersen BL* . KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development. Oncogene. 2024 Dec;43(50):3673-3687. doi: 10.1038/s41388-024-03196-w. Epub 2024 Oct 23. PMID: 39443726
  3. Wang L, Pattnaik A, Sahoo SS, Stone EG, Zhuang Y, Benton A, Tajmul M, Chakravorty S, Dhawan D, Nguyen MA, Sirit I, Mundy K, Ricketts CJ, Hadisurya M, Baral G, Tinsley SL, Anderson NL, Hoda S, Briggs SD, Kaimakliotis HZ, Allen-Petersen BL , Tao WA, Linehan WM, Knapp DW, Hanna JA, Olson MR, Afzali B, Kazemian M. Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark. Nat Commun. 2024 Aug 24;15(1):7288. doi: 10.1038/s41467-024-51859-9. PubMed PMID: 39179644
  4. Grygoryev D, Ekstrom T, Manalo E, Link JM, Alshaikh A, Keith D,  Allen-Petersen BL , Sheppard B, Morgan T, Soufi A, Sears RC, Kim J. Sendai virus is robust and consistent in delivering genes into human pancreatic cancer cells. Heliyon. 2024 Feb28;10(5):e27221 doi: 10.1016/j.heliyon.2024. e27221 PMID: 38463758
  5. Hopkins K, Buno K, Romick N, Freitas dos Santos AC, Tinsley SL, Wakelin E, Kennedy J, Ladisch M, Allen-Petersen BL* , Solorio L *. Sustained Degradation of Hyaluronic Acid using an In Situ Forming Implant. 2022 PNAS Nexus Sep 17;1(4):pgac193 PMID: 36714867  *co-corresponding 
  6. Shah VM, Dorrell C, Al-Fatease A, Allen-Petersen BL , Woo Y, Bortnyak Y, Gheewala R, Sheppard BC, Sears RC, Alani AW. Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. Pharmaceutics. 2022 Mar 26;14(4). doi: 10.3390/pharmaceutics14040713. PMID: 35456547
  7. Tinsley SL, Allen-Petersen BL . PP2A and cancer epigenetics: a therapeutic opportunity waiting to happen. NAR Cancer. 2022 Feb 1;4(1):zcac002. PMID: 35118387
  8. Farrington CC, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen BL , Janghorban M, Chung E, Wolczanski G, Galsky M, Sears R, Sangodkar J, Narla G. Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. J Biol Chem. 2020 Jan 17;295(3):757-770. doi:10.1074/jbc.RA119.011443 PMID: 31822503
  9. Allen-Petersen BL and Sears RC. Mission possible: advances in c-MYC therapeutic targeting in cancer. BioDrugs 2019 2019Aug 7. doi: 10.1007/s40259-019-00370-5
  10. Auciello FR*, Bulusu V*, Oon C, Tait-Mulder J, Berry M, Bhattacharyya S, Tumanov S, Allen-Petersen BL , Link J, Kendsersky ND, Vringer E, Schug M, Novo D, Hwang RF, Evans RM, Nixon C, Dorrell C, Morton JP, Norman JC, Sears RC, Kamphorst JJ*, Sherman MH*. A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. Cancer Discov. 2019 Mar 5. doi: 10.1158/2159-8290.CD-18-1212 *Equal Contribution
  11. Langer EM*, Allen-Petersen BL *, King SM, Kendsersky ND, Turnidge MA, Kuziel GM, Riggers R, Samatham R, Amery TS, Jacques SL, Sheppard BC, Korkola JE, Muschler JL, Thibault T, Chang YH, Gray JW, Presnell SC, Nguyen DG, Sears RC. Modeling tumor phenotypes in vitro with three-dimensional bioprinting. Cell Rep. 2019 Jan 15;26(3):608-623.e6. doi: 10.1016/j.celrep.2018.12.090 *Equal Contribution
  12. Allen-Petersen BL , Risom T, Feng Z, Wang Z, Jenny ZP, Morton JP, Sansom OJ, Lopez CD, Sheppard BC, Christensen DJ, Ohlmeyer M, Narla G, and Sears RC. PP2A activation and mTOR inhibition synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma. Cancer Res. 2019 Jan1;79(1):209-219. doi: 10.1158/0008-5472.CAN-18-0717
  13. Allen-Petersen BL and Sears RC. The use of protein phosphatase 2A activators in combination therapies for pancreas cancer. Oncotarget 2019;10(21):2008-2009 doi.org/10.18632/oncotarget.26772
  14. Farrell AS*, Joly MM*, Allen-Petersen BL , Worth PJ, Lanciault C, Sauer D, Link J, Pelz C, Heiser LM, Morton JP, Muthalagu N, Hoffman MT, Manning SL, Pratt ED, Kendsersky ND, Egbukichi N, Amery TS, Thoma MC, Jenny ZP, Rhim AD, Murphy DJ, Sansom OJ, Crawford HC, Sheppard BC, Sears RC . MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nat Commun. 2017;8(1):1728. *Equal Contribution
  15. Allen-Petersen BL and Sears RC. RAS and MYC: Co-conspirators in Cancer. National Cancer Institute RAS Dialogue. 2017 cancer.gov/research/key-initiatives/ras/ras-central/blog/2017/myc-ras
  16. Janghorban M, Farrell AS, Allen-Petersen BL , Pelz C, Daniel CJ, Oddo J, Langer EM, Christensen DJ, Sears RC. Targeting c-Myc by antagonizing PP2A inhibitors in breast cancer. Natl. Acad. Sci. 2014 Jun 24; 111(25):9157-62
  17. Farrell AS, Allen-Petersen BL , Daniel CJ, Wang X, Wang Z, Rodriguez S, Impey S, Oddo J, Vitek MP, Lopez CD, Christensen DJ, Sheppard BC, Sears RC. Targeting Inhibitors of the Tumor Suppressor Protein Phosphatase 2A for the Treatment of Pancreatic Cancer. Mol Cancer Res. 2014 Jun; 12(6):924-39
  18. Allen-Petersen BL , Carter CJ, Ohm AM, Reyland ME. Protein kinase Cδ is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer. Oncogene. 2013 doi:10.1038/onc.2013.59
  19. Allen-Petersen BL *, Miller MR*, Neville MC, Anderson SM, Nakayama KI and Reyland ME. Loss of protein kinase C delta alters mammary gland development and apoptosis. Cell Death Dis. 2010 Jan;1(1):e17 * Equal Contribution
  20. Noble SL, Allen BL , Goh LK, Nordick K, Evans TC. Maternal mRNAs are regulated by diverse P body-related mRNP granules during early Caenorhabditis elegans development. J Cell Biol. 2008 Aug 11; 182(3):559-72
  21. Haas CS, Amin MA, Ruth JH, Allen BL , Ahmed S, Pakozdi A, Woods JM, Shahrara S, Koch AE. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum. 2007 Aug; 56(8):2535-48
  22. Haas CS, Amin MA, Allen BB , Ruth JH, Haines GK 3rd, Woods JM, Koch AE. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum. 2006 Jul 25; 54(8):2402-2414